Continuous measures of driving performance on an advanced office-based driving simulator can be used to predict simulator task failure in patients with obstructive sleep apnoea syndrome

Dipansu Ghosh, Samantha L Jamson, Paul D Baxter, Mark W Elliott

ABSTRACT

Introduction Some patients with obstructive sleep apnoea syndrome are at higher risk of being involved in road traffic accidents. It has not been possible to identify this group from clinical and polysomnographic information or using simple simulators. We explore the possibility of identifying this group from variables generated in an advanced PC-based driving simulator.

Methods All patients performed a 90 km motorway driving simulation. Two events were programmed to trigger evasive actions, one subtle and an alert driver should not crash, while for the other, even a fully alert driver might crash. Simulator parameters including standard deviation of lane position (SDLP) and reaction times at the veer event (VeerRT) were recorded. There were three possible outcomes: ‘fail’, ‘indeterminate’ and ‘pass’. An exploratory study identified the simulator parameters predicting a ‘fail’ by regression analysis and this was then validated prospectively.

Results 72 patients were included in the exploratory phase and 133 patients in the validation phase. 65 (32%) patients completed the run without any incidents, 45 (22%) failed, 95 (46%) were indeterminate. Prediction models using SDLP and VeerRT could predict ‘fails’ with a sensitivity of 82% and specificity of 96%. The models were subsequently confirmed in the validation phase.

Conclusions Using continuously measured variables it has been possible to identify, with a high degree of accuracy, a subset of patients with obstructive sleep apnoea syndrome who fail a simulated driving test. This has the potential to identify at-risk drivers and improve the reliability of a clinician’s decision-making.

INTRODUCTION

On average, patients with obstructive sleep apnoea syndrome (OSAS) are at increased risk of being involved in a road traffic accident, but not all patients with OSAS are unsafe drivers. Currently advice about an individual’s fitness to drive is based on the severity of the sleep-disordered breathing and daytime sleepiness, and their account of their driving.1–4 Although there is a trend towards increased likelihood of accidents with more severe sleep-disordered breathing, these are not sufficiently robust data on which to base decisions for an individual.5 There are conflicting data about the relationship between perceived sleepiness and the likelihood of being involved in an accident6 7 and between subjective and objective tests for increased daytime sleepiness.8–10 Driving requires alertness and also complex integrated higher cortical function; patients with OSAS may have neurological damage, which may impact on driving.11 Driving may therefore be impaired for reasons other than those just related to maintenance of alertness. The advice that a patient will receive about driving will also depend on their doctor’s attitude to risk and this is likely to be inconsistent in the absence of robust objective criteria. There is therefore a need for an objective test, which can help to inform the advice that clinicians give to patients with OSAS about driving.
Sleep disordered breathing

Table 1 Characteristics of the patient populations

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Exploratory study</th>
<th>Validation study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>54 (46–61)</td>
<td>52 (44–60)</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>65 (90)</td>
<td>118 (88)</td>
</tr>
<tr>
<td>BMI (kg/m²), median (IQR)</td>
<td>34 (30–37)</td>
<td>33 (30–37)</td>
</tr>
<tr>
<td>ESS, mean (IQR)</td>
<td>13 (7–16)</td>
<td>12 (7–16)</td>
</tr>
<tr>
<td>AHI (events/h), median (IQR)</td>
<td>32 (20–54)</td>
<td>25 (13–42)</td>
</tr>
<tr>
<td>ODI (events/h), median (IQR)</td>
<td>35 (22–55)</td>
<td>24 (13–44)</td>
</tr>
<tr>
<td>Years since first driving licence, median (IQR)</td>
<td>34 (25–40)</td>
<td>30 (30–38)</td>
</tr>
</tbody>
</table>

AHI, apnoea hypopnoea index; BMI, body mass index; ESS, Epworth Sleepiness Score; ODI, oxygen desaturation index.

able overnight sleep study (Emblettia, Medcare Flaga, Reykjavik, Iceland) or overnight oximetry were approached. Recruitment was biased towards patients considered for a trial of CPAP therapy. This was to generate a patient population at risk of road traffic accident and likely to have ‘events’ on the simulator.

Driving simulator (MiniSim)

Road layout and scenario

A 90 km three-lane motorway was developed with UK standard lane markings and signage. The road is composed of eight sections (each 9 km in length). One section of motorway takes approximately 7 min to drive (at 70 mph) and will be referred to as one epoch. All subjects had the procedures explained and had a four-epoch practice session before commencing the test proper. A ‘minor’ or ‘veer’ event was choreographed within epoch 4 of the test run; a vehicle swerves briefly into the driver’s lane, requiring an avoidance manoeuvre such as braking or swerving (or both). The vehicle is sufficiently far ahead that an alert driver should easily be able to avoid a collision. Throughout the drive, vehicles manoeuvre in and out of the subjects’ lane and they react to them as they would in real life. The ‘minor’ event is an extension of these manoeuvres. A ‘major’ or ‘brake’ event was inserted into epoch 8 and this also signalled the end of the run. Here, a vehicle ahead brakes heavily; even with full attention some subjects might not avoid a crash.

Measures and endpoints

Task failure was defined as hitting another vehicle, veering completely out of lane (except in response to an event) or

Figure 1 Driving simulator outcomes of all patients in the exploratory phase of the study.
spending more than 5% of the total study time (2.5 min) with two wheels out of the middle lane. There were four possible outcomes of the simulator runs; task failure unprovoked during the study; crashing into the vehicle in front at the ‘veer’ event; crashing into the vehicle in front only at the major event; no task failure at any time during the study run. Unprovoked task failure and crashes at the minor event should not happen during simulated driving and these subjects were considered to have ‘failed’ the test. Subjects who completed the test without meeting any of the task failure criteria defined above were deemed to have ‘passed’. The subjects who only crashed at the ‘brake’ event were deemed to be ‘indeterminate’.

The MiniSim recorded continuous measures of driving behavior, such as time it would take to collide into the lead vehicle were it to stop dead (minimum time headway, Hw), percentage time spent with minimum headway of <1 s (Hw1s), minimum time to collision (TTC) to the preceding vehicle, high-frequency steering (HFS), mean speed, standard deviation of lane position (SDLP), lane changes. For the purpose of analysis we used the mean values for each parameter in epochs 3, 5, 6 and 7, which were free of events and just require steady driving at approximately 70 mph. In addition, specific measures at the programmed events were also recorded, including speed on approach to collision and reaction times (RTs).

Study design and analysis
The study was divided into two phases. In the first phase we explored whether any of the continuous (eg, SDLP, HFS, TTC, Hw1s) and event specific (eg, RT) simulator variables recorded could predict the outcomes on the MiniSim. We compared these measures of driving performance between different categories of patients using one-way analysis of variance and t-tests with Bonferroni’s multiple testing correction. Binary logistic regression analysis was used to test the hypothesis that a ‘fail’ could be predicted from continuous measures of driving behaviour and thereby explore the possibility of developing a predictive model. Receiver operating characteristic (ROC) curve analyses were performed to calculate the discriminative power of the models and identify optimal cutoffs for probability score. The sensitivity, specificity and predictive powers of the models were calculated using the cutoff values. The curves generated for each model were compared using methods described by DeLong et al.24

In the second phase we validated the findings from the exploratory study in a different population. We compared ROC curves and used a two-sample z-test for comparing proportions.

Detailed methodology and definitions of simulator parameters are provided in the online supplement.

### RESULTS

#### Subject population

Two hundred and twenty-nine patients participated in the study. Eighty-four patients were recruited for the first phase and 145 for the second. Twelve patients were excluded from each of the two phases due to inability to complete the two runs (practice and test), time constraints, simulator sickness (n=4) and inability to sit continuously for 50 min. The characteristics of the 205 patients who completed the studies are described in table 1. There were no differences between the two cohorts except that the apnoea hypopnoea index in patients in the first phase was significantly higher (p=0.009).

#### Exploratory study

Forty-one (57%) subjects completed the simulator runs successfully. Thirty-one (45%) had some form of task failure (figure 1). Of the 15 subjects who failed, 9 also crashed at the brake event. Two subjects could not complete the full test run as they veered out of lane into the central reservation. One of them fell asleep.

#### Simulator variables

Comparisons between the three groups ‘fail’, ‘indeterminate’ and ‘pass’ are shown in table 2. There were significant differences in the ability to maintain lane position (figure 2), minimum time to collision with the vehicle in front (TTC), minimum time headway (Hw), HFS (figure 3) and RT at the veer and brake events (figure 4). These significant differences were

---

**Table 2** Comparisons between the three groups in exploratory phase: fail, indeterminate and pass

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Fail (n=13), mean (SD)</th>
<th>Indeterminate (n=18), mean (SD)</th>
<th>Pass (n=41), mean (SD)</th>
<th>One-way p Value</th>
<th>Bonferroni’s multiple testing correction: is p&lt;0.05?</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDLP 3</td>
<td>0.66 (0.2)</td>
<td>0.44 (0.13)</td>
<td>0.37 (0.08)</td>
<td>&lt;0.001</td>
<td>Fail vs indeterminate: No, Fail vs pass: No, Indeterminate vs pass: Yes</td>
</tr>
<tr>
<td>HFS 3</td>
<td>0.37 (0.09)</td>
<td>0.26 (0.06)</td>
<td>0.27 (0.07)</td>
<td>&lt;0.001</td>
<td>Fail vs indeterminate: No, Fail vs pass: No, Indeterminate vs pass: Yes</td>
</tr>
<tr>
<td>TTC 3</td>
<td>1.97 (1.69)</td>
<td>5.84 (3.34)</td>
<td>6.67 (4.9)</td>
<td>0.002</td>
<td>Fail vs indeterminate: No, Fail vs pass: No, Indeterminate vs pass: Yes</td>
</tr>
<tr>
<td>Hw1s 3</td>
<td>29.6 (28.9)</td>
<td>17.5 (16.2)</td>
<td>13.5 (13)</td>
<td>0.296</td>
<td>Fail vs indeterminate: No, Fail vs pass: No, Indeterminate vs pass: Yes</td>
</tr>
<tr>
<td>Hw 3</td>
<td>0.21 (0.23)</td>
<td>0.393 (0.21)</td>
<td>0.57 (0.24)</td>
<td>&lt;0.001</td>
<td>Fail vs indeterminate: Yes, Fail vs pass: No, Indeterminate vs pass: No</td>
</tr>
<tr>
<td>Speed 3</td>
<td>65 (8)</td>
<td>67 (3)</td>
<td>67 (3)</td>
<td>0.535</td>
<td>Fail vs indeterminate: No, Fail vs pass: No, Indeterminate vs pass: No</td>
</tr>
<tr>
<td>VeerRT (s)</td>
<td>2.3 (0.78)</td>
<td>1.68 (0.33)</td>
<td>1.38 (0.25)</td>
<td>&lt;0.001</td>
<td>Fail vs indeterminate: Yes, Fail vs pass: Yes, Indeterminate vs pass: No</td>
</tr>
<tr>
<td>BrakeRT (s)</td>
<td>3.6 (0.6)</td>
<td>3.5 (0.9)</td>
<td>2.2 (0.6)</td>
<td>&lt;0.001</td>
<td>Fail vs indeterminate: No, Fail vs pass: Yes, Indeterminate vs pass: Yes</td>
</tr>
</tbody>
</table>

BrakeRT, reaction time at the brake event; HFS, mean of HFS in epoch 3; Hw, minimum headway in epoch 3; Hw1s, percentage of time spent with headway under 1 s in epoch 3; SDLP, mean SDLP in epoch 3; Speed, mean speed in epoch 3; TTC, mean of TTC in epoch 3; VeerRT, reaction time at the veer event.

---

**Figure 2** Distribution of mean of SD of lane position (SDLP) in epoch 3 between the three groups.
maintained irrespective of the epochs (3, 5, 6 or 7) used and therefore, for simplicity, ease of presentation and because this may allow the test to be shortened in future, only data from epoch 3 are presented and used in the regression analyses. There was a clear distinction between 'fails' and the rest, but only the VeerRT and Hw 3 were significantly different between the ‘pass’ and ‘indeterminate’ groups.

Regression analysis and ROC curves
Two predictive models emerged in differentiating ‘fails’ from the others. Model 1—including only the SDLP 3, and Model 2—including a combination of SDLP 3 and VeerRT.

Model 2 had higher predictive power. Figure 5 compares the two models using ROC curve analysis and reinforces the finding from the regression analysis. The first model has an area under the curve (AuC) of 0.89 and the second 0.93. The difference between the two ROC curves was not significant (p = 0.132). Table 3 compares the sensitivities and specificities of the two models at the chosen cutoffs. The chosen cutoffs (0.15 for model 1 and 0.3 for model 2) quoted here are a compromise between extremes of high sensitivity and high specificity, giving equal weight to both.

The details of the extremes of cutoffs, regression coefficients and equations are provided in the online supplement.

A similar regression analysis was performed excluding those who had ‘failed’ to distinguish between ‘indeterminates’ and ‘passers’. AuC in the ROC curve analysis was 0.84. The sensitivity of that model to identify ‘pass’ was 97% (95% CI 86% to 99%) with 53% (95% CI 26% to 79%) specificity; VeerRT and Hw were the parameters in the equation. The positive predictive value was 84% (95% CI 70% to 93%) and the negative predictive value only 88% (95% CI 51% to 99%) using a cutoff of 0.5. Hence using simulator data the ‘failed’ group could be predicted with much greater certainty than the ‘indeterminate’ group.

Validation study
One hundred and thirty-three patients were analysed for the validation study and the outcomes are described in figure 6. Most subjects who failed fulfilled more than one task failure criterion. Of the 13 subjects who could not complete the full run, 4 also had an unprovoked crash and 4 crashed at the veer event. Nine of

Table 3  Comparing optimum sensitivities and specificities of the two models

<table>
<thead>
<tr>
<th>Models</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Positive predictive value (%)</th>
<th>Negative predictive value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td>76 (46 to 95)</td>
<td>84 (72 to 92)</td>
<td>53 (25 to 75)</td>
<td>94 (84 to 99)</td>
</tr>
<tr>
<td>(cutoff 0.15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 2</td>
<td>82 (48 to 98)</td>
<td>96 (87 to 99)</td>
<td>82 (48 to 98)</td>
<td>96 (87 to 99)</td>
</tr>
<tr>
<td>(cutoff 0.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: 95% CI.
them also failed on lane criteria. Of the 19 failed subjects who completed the full run, 12 also crashed at the brake event. Table 4 compares the three categories. The results are similar to the first phase of the study, broadly showing the same relationship between the simulator parameters.

We could apply the equation from model 1 to 133 subjects and model 2 to 115 subjects due to unavailability of either of the two parameters; some subjects did not brake at the veer event and avoided a crash just by swerving; others crashed before epoch 3 and hence SDLP 3 was not available. A ROC curve was constructed with the predicted probability score for model 2 generated by the equation derived in the exploratory study for each subject. The AuC was 0.9 compared with 0.93 in the exploratory study. The difference between the two curves was not significant (p=0.570). Furthermore the calculated sensitivities and specificities at the chosen cutoffs were not significantly different between the two cohorts when compared using z-tests, confirming that the findings of the exploratory study are valid in a different population (table 5).

**DISCUSSION**

We have shown in two different cohorts that with the MiniSim it is possible to distinguish, with a high degree of confidence, patients with OSAS who unequivocally crash during simulated driving from those who are able to complete a 50 min drive without incident. We can also identify a group, but with less confidence, whose performance is intermediate. Not only was their response at the veer event different from the others but there was a clear hierarchical pattern for other parameters (SDLP, HFS, Hw and BrakeRT); subjects who ‘failed’ were worst, those who ‘passed’ the best, with the ‘indeterminates’ in the middle.

The sensitivities, specificities and the predictive values can be calculated for different cutoffs; the one chosen will depend upon the attitude to risk. At one extreme, all accidents should be prevented and anybody with the slightest possibility of having an accident should be identified. At the other extreme, the emphasis will be on being as sure as possible that an individual is an unsafe driver. We have quoted compromise values for cutoffs, giving equal weight to sensitivity and specificity; others might choose a different value. Examples are given in the online supplement.

We deliberately tried to recruit patients at risk of having problems driving; many completed a 50 min run on a realistic motorway without incident. This can potentially overestimate the sensitivities and specificities compared with a general OSAS cohort. However, in real life this test would probably be used on patients with OSAS who are considered to be high risk. One problem with previous simulator studies was the number of crashes or events during the study. In a study by Juniper et al patients with OSAS had a median of 5.2 off-road events per hour. Similarly Turkington et al reported an average of 24 off-road events per hour in their study using a divided attention driving simulator. Even patients with severe OSAS do not have multiple events during 20 min of on-road driving. The criteria that we used for ‘fail’ are realistic and understandable to patients. This is very important if the test is to have credibility; an individual who fails on the simulator because they go off road...
Sleep disordered breathing

Table 5  Sensitivities, specificities and predictive values of the two models at chosen cutoffs applied to the exploratory and validation cohorts and p values for a two-sample z-test comparing the sensitivities and specificities of the chosen cutoffs in the two populations

<table>
<thead>
<tr>
<th>Models</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Positive predictive value</th>
<th>Negative predictive value</th>
<th>p Values for z-test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1 (cutoff 0.15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exploratory cohort</td>
<td>76 (46 to 95)</td>
<td>84 (72 to 92)</td>
<td>53 (25 to 75)</td>
<td>94 (84 to 99)</td>
<td>0.507 0.866</td>
</tr>
<tr>
<td>Validation cohort</td>
<td>60 (41 to 77)</td>
<td>85 (77 to 91)</td>
<td>55 (38 to 72)</td>
<td>88 (80 to 93)</td>
<td></td>
</tr>
<tr>
<td>p Values for z-test</td>
<td>0.507</td>
<td>0.866</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 2 (cutoff 0.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exploratory cohort</td>
<td>82 (48 to 98)</td>
<td>96 (87 to 99)</td>
<td>82 (48 to 98)</td>
<td>96 (87 to 99)</td>
<td></td>
</tr>
<tr>
<td>Validation cohort</td>
<td>60 (36 to 81)</td>
<td>93 (85 to 97)</td>
<td>63 (38 to 84)</td>
<td>92 (84 to 96)</td>
<td></td>
</tr>
<tr>
<td>p Values for z-test</td>
<td>0.384</td>
<td>0.342</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: 95% CI.

predicted from parameters of which the patient is unaware is an advantage. An objective test is an advance over the current situation in which inconsistent advice is given, based upon unreliable data, coloured by the clinician’s individual stance on driving and accident risk. The work described here is the first step towards the development of an objective test that could have a major impact on the reliability of the advice provided.

Acknowledgements We are grateful to Michael Daly, Tony Horrobin and Hamish Jamson from the Institute for Transport Studies for their contribution to the development and running of the simulator. We are thankful to the contributions of research nurse Craig Armstrong, sleep physiologist Sue Watts, specialist nurses Martin Latham, Jampa Choedon, Mitchell Nix, Lisa Emmett, healthcare assistant Anne Kellett and Audrey Rowe and Susan Leigh from the Sleep Services administrative team.

Contributors DG: design of study, data collection, analysis, writing the paper. SLJ: design of study, analysis, writing the paper. FBD: design, statistical analysis, writing the paper. MWA: concept, design of study, writing the paper.

Funding The study was partly supported by an unrestricted grant from ResMed for healthcare assistant time to supervise simulator runs.

Competing interests None.

Patients consent Obtained.

Ethics approval NHS Research Ethics Committee, York.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Journal club

Chronic disease management for tobacco dependence

This randomised control trial compared the efficacy of utilising chronic disease management principles for tobacco dependence using a tailored intervention with standard care. As tobacco dependence is a chronic relapsing condition, the tailored intervention was chosen to account for possible interim setbacks.

Four hundred and forty-three eligible participants received five telephone-counselling calls and 4 weeks of nicotine replacement therapy. They were randomised to receive continuing counselling and nicotine replacement therapy for 1 year (longitudinal care, LC) or to receive one additional call at 8 weeks (evidence-based usual care, UC). The primary outcome was 6 months of prolonged abstinence, measured at 18 months following initial quit date. Secondary outcomes included abstinence rates before 6 months and smoking reduction.

At 18 months, 30.2% of LC participants reported 6 months of abstinence from smoking, compared with 23.5% in UC. Prior to 6 months, abstinence rates were slightly higher with UC than LC. At all time points, those who did not quit had greater smoking reduction with LC than UC (statistically significant only at 12 months). With LC, quit rates rose throughout the year without reaching a plateau, suggesting that extending treatment further may be beneficial.

One limitation of this study was the difficulty in differentiating between the effects of behavioural and medical treatment. Results were not biochemically confirmed, but the study population was believed to be low-risk for incorrectly reporting smoking status. The LC model allowed counsellors to adjust treatment in response to smokers’ experiences of quitting and to positively reinforce the option of interim smoking reduction. Chronic management appears to be a feasible approach to increase long-term abstinence.


Correspondence to Dr Harshani M Chandrasekera, FY2, Department of Thoracic Medicine, The Royal Free Hospital, Pond Street, London NW3 2QG, UK; harshani.chandrasekera@nhs.net

Published Online First 27 January 2012
Thorax 2012;67:821. doi:10.1136/thoraxjnl-2012-201586
Continuous measures of driving performance on an advanced office-based driving simulator can be used to predict simulator task failure in patients with obstructive sleep apnoea syndrome

Dipansu Ghosh, Samantha L Jamson, Paul D Baxter and Mark W Elliott

Thorax 2012 67: 815-821 originally published online May 5, 2012
doi: 10.1136/thoraxjnl-2011-200699

Updated information and services can be found at:
http://thorax.bmj.com/content/67/9/815

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2012/05/04/thoraxjnl-2011-200699.DC1

References
This article cites 25 articles, 6 of which you can access for free at:
http://thorax.bmj.com/content/67/9/815#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/